InMed Pharmaceuticals INM-089 Presented Neuroprotection Of Photoreceptors As Well As Improved Photoreceptors Function; Improved Integrity Of Retinal Pigment Epithelium; And Reduction In Extracellular Autofluorescent Deposits, A Hallmark Of Dry AMD

4/16/24 2:45:14 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INM alert in real time by email

Get the next $INM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INM

Date	Price Target	Rating	Analyst
11/29/2021	$6.00	Buy	HC Wainwright & Co.

More analyst ratings

$INM
Market Insights

Live Market Insights

Inmed Pharmaceuticals Granted U.Ss. Patent #12042479 Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders
7/23/24 10:11:02 AM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
6/6/24 1:39:18 PM ET
$AEMD
$AIRJ
$AONC
$ASNS
Medical/Dental Instruments
Health Care
Industrial Machinery/Components
Industrials
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Smartsheet Inc. (NYSE:SMAR) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and announced an inaugural $150 million share repurchase program. Smartsheet reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $263.00 million which beat the analyst consensus estimate of $258.28 million, according to data from Benzinga Pro. The company also announced that its board authorized the repurchase of up to $150 million of its common stock. Smartsheet shares jumped 13.1% to $42.71in the pre-market trading sessio
6/6/24 8:16:55 AM ET
$AEMD
$ASNS
$ASST
$CXM
Medical/Dental Instruments
Health Care
Telecommunications Equipment
Telecommunications

$INM
Financials

Live finance-specific insights

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w
9/19/22 6:00:00 PM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,
2/14/22 7:34:02 PM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available
2/10/22 7:30:00 AM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care

$INM
Press Releases

Fastest customizable press release news feed in the world

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMed
6/12/24 7:00:00 AM ET
$ASPI
$ATRA
$CIA
$CLNN
Major Chemicals
Industrials
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 48
6/11/24 7:00:00 AM ET
$ASPI
$ATRA
$CIA
$CLNN
Major Chemicals
Industrials
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol ("CBN") cream versus the control cream alone.The results for non-wound itch were not statistically significant in favor of INM-755 CBN cream due, in part, to the clinically important anti-itch effect of the underlying control cream.INM-755 CBN cream demonstrated a favorable safety and tolerability profile.InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa ("EB") and other itch-related skin conditions.Vancouver, British Columbia--(Newsfile Corp. - June 22, 2023) - InMed Pharmaceuticals Inc. (NASDAQ:INM)
6/22/23 7:30:00 AM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care

$INM
Leadership Updates

Live Leadership Updates

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid
12/12/22 6:47:35 PM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care
InMed Announces Changes to its Board of Directors
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public
8/9/22 7:30:00 AM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care
InMed Announces Appointment of Chief Operating Officer
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa
7/18/22 7:30:00 AM ET
$INM
Biotechnology: Pharmaceutical Preparations
Health Care

InMed Pharmaceuticals INM-089 Presented Neuroprotection Of Photoreceptors As Well As Improved Photoreceptors Function; Improved Integrity Of Retinal Pigment Epithelium; And Reduction In Extracellular Autofluorescent Deposits, A Hallmark Of Dry AMD

Chat with this insight

Recent Analyst Ratings for $INM

$INM Market Insights

Live Market Insights

Inmed Pharmaceuticals Granted U.Ss. Patent #12042479 Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

$INM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc. (Amendment)

$INM SEC Filings

InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$INM Financials

Live finance-specific insights

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

$INM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

$INM Press Releases

Fastest customizable press release news feed in the world

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

$INM Leadership Updates

Live Leadership Updates

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

InMed Announces Changes to its Board of Directors

InMed Announces Appointment of Chief Operating Officer

$INM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

$INM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Consultant Mancini Alexandra Diane Janet sold $42 worth of shares (240 units at $0.18), closing all direct ownership in the company (SEC Form 4)

SEC Form 4 filed by Woudenberg Michael

SEC Form 4 filed by Adams Eric A

Recent Analyst Ratings for
$INM

$INM
Market Insights

$INM
Large Ownership Changes

$INM
SEC Filings

$INM
Financials

$INM
Insider Purchases

$INM
Press Releases

$INM
Leadership Updates

$INM
Analyst Ratings

$INM
Insider Trading